Emerald Health Therapeutics Appoints Chief Operating Officer
May 22 2019 - 6:00AM
Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH;
OTCQX:EMHTF) has appointed Sean Rathbone as Chief Operating
Officer. Mr. Rathbone brings expertise in operational leadership,
corporate process management, technology advancement, and waste
reduction and raw materials refinement.
“Mr. Rathbone is an industrial engineer
experienced in driving large-scale operational mandates with
consumer-focused Fortune 500 companies,” said Dr. Avtar Dhillon,
President and Executive Chairman of Emerald. “As Emerald continues
to expand and serve the growing demand for quality cannabis
products across Canada, Mr. Rathbone will improve and introduce
processes, policies and technologies to help meet production goals
while maintaining company-wide performance standards and
operational efficiencies.”
Mr. Rathbone served as Vice President,
Manufacturing, Western Canada at Agropur; Manager, Manufacturing
R&D at BDO Canada, LLP; Operations Area Manager at Amazon
Canada Fulfillment Service, Ltd.; and Director, World Class
Manufacturing at Molson Coors. He started his career at Unilever in
South Africa.
He holds a Master of Business Administration
from Heriot-Watt University, Edinburgh, Scotland and a Bachelor of
Mechanical Engineering Technology from the University of
Witwatersrand, Johannesburg, South Africa.
About Emerald Health
Therapeutics
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis. Its 50%-owned Pure Sunfarms joint
venture in BC is licensed and fully planted in the first of its two
1.1 million square foot greenhouses. The capacity of each
greenhouse is estimated to exceed 75,000 kg of cannabis annually.
Emerald’s Verdélite operation in Saint Eustache, Québec is
completing the build-out of its 88,000 square foot indoor
cultivation facility and is scaling up production. Emerald has
contracted for approximately 1000 acres of hemp in 2019 to 2022
with the objective of extracting low-cost cannabidiol. Emerald has
secured exclusive strategic partnerships for large scale extraction
and softgel encapsulation, as well as for proprietary technology to
enhance cannabinoid bioavailability. Its team is highly experienced
in life sciences, product development, large-scale agri-business,
and marketing, and is focused on developing proprietary,
value-added cannabis products for medical and adult-use
customers.
Emerald is part of the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products aimed at
providing wellness and medical benefits by interacting with the
human body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:
Rob Hill, Chief Financial Officer(800) 757 3536
Ext. #5
Investor Relations(800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include projected job creation figures at our operating facilities;
production and processing capacity of various facilities; expansion
of facilities; and anticipated production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Apr 2023 to Apr 2024